Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: A case report

Tumori

Volumn 100, Issue 1, 2014, Pages

  Bordi, Paola ^a   Tiseo, Marcello ^a   Bortesi, Beatrice ^a   Naldi, Nadia ^a   Buti, Sebastiano ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Acquired resistance; Afatinib; Brain metastases; EGFR mutation; EGFRT790M; NSCLC

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; METHIONINE; PEMETREXED; STEROID; THREONINE; ZOLEDRONIC ACID;

ADRENAL METASTASIS; ADULT; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EGFR GENE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; TRANSBRONCHIAL ASPIRATION; VOMITING;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; METHIONINE; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THREONINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897011664     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib of Carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361(10): 947-957; 2009.
2. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol, 13 (3): 239-246, 2012.
3. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3: 75ra26, 2011.
4. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W: HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov, 2: 922-933, 2012.
5. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Retting WJ, Meyerson M, Solca F, Greulich H, Wong KK: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27: 4702-4711, 2008.
6. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC: Afatinib versus placebo for patients with advanced, metastatic nonsmall-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 13: 528-538, 2012.
7. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, Duan J, Yang L, Wu M, Liang Z, Wang Y, Kang X, Wang J: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol, 30: 3077-3083, 2012.
8. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol, 28: 3965-3972, 2010.